Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20303253 | 0.98 | CTSL (0.42) | CTSLCTSBCTSKLMNAEPHX2 | |
| SCHEMBL19023658 | 0.91 | LPL (0.39) | CTSLCTSBCTSKEPHX2SLC1A3 | |
| SCHEMBL17220074 | 0.88 | GPR119 (0.38) | CTSLCTSBCTSKEPHX2SLC1A3 | |
| SCHEMBL29277070 | 0.83 | ITGB3 (0.41) | GPR119 | |
| SCHEMBL12813517 | 0.81 | GPR119 (0.39) | CTSLCTSBCTSKEPHX2ALDH1A1 | |
| SCHEMBL1241577 | 0.81 | LIPG (0.42) | CTSLCTSBCTSKSLC1A3SLC1A2 | |
| SCHEMBL27258938 | 0.79 | CTSL (0.45) | CTSLCTSBCTSKLMNAEPHX2 | |
| SCHEMBL12813505 | 0.79 | GPR119 (0.38) | ALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL26635122 | 0.77 | GPR119 (0.58) | GPR119 | |
| SCHEMBL18185631 | 0.77 | CTSL (0.39) | CTSLCTSBCTSKALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CTSL 222/4885CTSB 1244/4885CTSK 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.